|
|
espa�ol - fran�ais - portugu�s |
Search
|
EC Measures Concerning Meat and Meat Products (Hormones) Complaint by the United States Report of the Panel (Continued)
Dr. Lucier
336. Thank you, Mr. Chairman.
I just wanted to make a few comments regarding Dr. Epstein's
presentation. One regarding the presence of the oestrogen receptor
in various tissues of the body. He had made the point that there
were oestrogen caused tumours in numerous sites. It is also true
that oestrogen receptors are found in every tissue of the body,
so there is no reason to think that oestrogen action isn't occurring
through a normal receptor mediated pathway. That doesn't mean
genotoxic events aren't also occurring, but it's clear that classical
receptor mediated events would be occurring as well. The other
point relates to the increased incidences of some tumours occurring
in various countries in the world. Regarding testicular cancer,
I think that it's probably true that there is a real increase
in testicular cancer and this increase appears to be predominant
in young men which is especially disturbing. Why this is occurring,
no one really knows, but as a public health person it is very
disturbing. There is no reason however to think that this has
to be associated with oestrogen, there are a lot of other kinds
of things that could be causing that, so there is not a direct
link to it, although that increase is in fact a real one. Regarding
breast cancer, that is also likely increasing. However, one can't
necessarily attribute that to exposure to exogenous external oestrogens.
There are several studies in the literature which suggest that
or demonstrate that exposure to genotoxic agents during the time
that a woman is a teenager causes a dramatic increase in breast
cancer. This was shown in atomic bomb survivors from Japan.
Those women who survived the atomic bomb, who were teenagers at
the time, had very elevated risk of breast cancer later in life,
women who survived who were in their 20s or 30s had no increase
in risk and there is very plausible biology for this which I won't
go into. It's also been shown now in three publications that
women who start smoking as teenagers have a higher increase in
breast cancer later in life, whereas if they start smoking later,
they do not. So there are a lot of reasons why exposure to genotoxic
agents could be accounting for the rise in breast cancer rates
that are seen throughout the world. So we need to be cognisant
of other factors and not just blame the exogenous oestrogens for
everything. Regarding the oral contraceptive issue, I think Dr.
Epstein is probably right that there would be an increase in breast
cancer risk for women who start taking the pill very young because
that extends the period of time in which they are exposed to high
levels of oestrogen and this is a known risk factor for breast
cancer. The same exposures a little bit later probably wouldn't
have an increase, so when you average everything out together
you don't get a statistically significant increase in breast cancer
from oral contraceptives. I don't think that anyone is challenging
the fact that oestrogens are carcinogenic, IARC is classified
conjugated oestrogens as a known human carcinogen, they have classified
oral contraceptives as an ... [tape ends]
... carcinogen based on an increase
of liver cancer not on the increase in breast cancer. They have
also classified tamoxifen as a known human carcinogen because
of its oestrogenic activity in the uterus. I don't think that
anyone is disputing that fact that oestrogens do cause cancer.
Chairman
337. Thank you.
Dr. McLean
338. Just by way of explanation,
I did not mean to mislead and I can see how that appeared. I
was talking in the context of tumours relating to the use of hormones
as growth promotants, and I just make one observation that the
increase in tumours occurs in those countries where the use of
growth promotant is not widespread and the increase began before
the hormonal growth promotants received widespread use. But it
was in the context of the hormonal growth promotants rather than
an increase in cancer per se that I meant to convey, and
if I misled then I apologise.
Chairman
339. Thank you. Mr. Christoforou
can I come back to you. Oh Dr. Arnold, you wanted to speak as
well, sorry.
Dr. Arnold
340. Just a short remark, Mr.
Chairman. Dr. Liehr and Dr. Cavalieri have proposed interesting
mechanisms how oestrogens could induce cancer by genotoxic mechanisms.
The Panel should know that other well-known people working with
other models came to different views. For example, I mentioned
Dr. Schulte-Hermann who is a well-known expert in rodent liver
carcinogenesis. He says for the hormones to exert their action,
there must be some pre-neoplastic lesions already present in the
animals, and although his evidence is also not complete, he has
quite a lot of data supporting his ideas. He for example has
shown that the incidence of tumours after oestrogen treatment
depends on the age of the animals at the time they start the treatment.
And he has developed experimental techniques to reduce the number
of pre-neoplastic lesions by restricting the diet, and he could
show that under these conditions the incidence of tumour formation
was lower when he started with old animals he kept on the restricted
diet and then administered oestrogens. So there is some evidence
in other models that perhaps there is no need that oestrogens
are complete carcinogens but the first step could be an unknown
initiation, the formation of pre-neoplastic lesions and then in
addition the hormone promotes the further development. Thank
you.
Chairman
341. Thank you very much. Can
we go to your next comment and question?
Mr. Christoforou (EC)
342. We have been addressing
until now, the potential at least genotoxic effects of the natural
hormones. But three of the hormones in dispute in this case also
are synthetic. They don't occur naturally by the other animals.
So we would like also to address the potential genotoxic and
carcinogenic effects of the synthetic hormones. I would give
the floor with your permission to Dr. Metzler who has produced
a paper and who will after this short presentation conclude by
framing a question to the scientists. Thank you.
Dr. Metzler (EC)
343. Thank you Mr. Chairman.
Although the synthetic oestrogens or I would rather call them
xenobiotic oestrogens and androgens, trenbolone and zeranol have
been far less thoroughly studied in terms of their genotoxicity,
they have most been subject to routine toxicological testing which
is difficult to pick up the genotoxicity of hormonal carcinogens.
Nevertheless, there is some evidence that these xenobiotic hormones
also are genotoxic and I'd just briefly summarize the evidence.
There are data from three different laboratories showing that
there is DNA binding at a low but significant amount or degree
with a covalent index of about 10. There is induction of chromosomal
damage in mammalian cells by trenbolone and other by the non-hormonally
active isomer diethyl trenbolone and there is evidence for cell
transformation in vitro in different laboratories. For
zeranol there is also evidence for DNA binding with a similar
covalent binding index and for closely related compounds, zeralenone
there is recent evidence of DNA adducts in vivo in mice
in different organs. So although there are not many studies available,
the few studies indicate that there is also genotoxic potential
for these xenobiotic hormones and I would like to finish this
brief presentation by addressing a question to Dr. Lucier.
Dr. Lucier has indicated that for the natural hormones it does
not make much sense or he called it irrelevant to discriminate
between genotoxic and non-genotoxic compounds. How would you
view this issue for the xenobiotic compounds?
Dr. Lucier
344. Before I answer, you have
to answer one of mine before I answer your question Manfred.
What is, at the risk of getting too technical, what is the evidence
for the DNA adduct formation for zeralenone or zeranol? Is this
simple binding of radioactivity to a DNA fraction or has altered
nucleoside isolated and characterized?
Dr. Metzler (EC)
345. For zeralenone or the microtoxin,
or the micro-oestrogen I should probably say, there has been a
recent study with the post-labelling assay indicating in vivo
in mice both in the kidney and in the liver a level of adducts,
of various adducts as shown by the post-labelling assay at the
level of about 1,000 nucleitides, modified nucleitides per 10(?)
nucleitides. So it's such a spining of discrete adducts that
shown for zeralenone. No such study has been done for zeranol
to my knowledge, for the growth promotant.
Dr. Lucier
346. One other quick question.
Is it possible that P-30 post-labelling which doesn't characterize
an individual adduct, is it possible that that is just arising
because a change in self-proliferation rates because when a cell
divides, of course, it loses its DNA adduct, or if it doesn't
divide it keeps its adducts. So a measurement of the endogenously
occurring adducts could lead to an alteration in the apparent
number but not be related to the zeranol itself. In other words,
so that adduct hasn't been characterized it's just been seen as
a spot on a TLC plate?
Dr. Metzler (EC)
347. Well these adducts have
been seen as spots but there were controls on untreated animals
of course and there were also species differences like in rats.
None of these adducts were seen with zeralenone, they were only
seen in mice. So there is a species difference which also is
in favour of real adduct.
Dr. Lucier 348. Sorry Mr. Chairman for that digression, but I needed that information to answer Dr. Metzler's question. The adducts that may arise from synthetic materials are likely different and of more concern than the ones, in terms of a risk assessment, than the ones that arise from the naturally-occurring ones, because we already know that there is a given body burden of the naturally-occurring oestrogens. So whether DNA adduct formation is occurring or whether its cell replication you are just adding a very small amount to an existing burden, whether it be genotoxic or whether it be non-genotoxic so that mechanism is irrelevant as Manfred said for the naturally-occurring oestrogens. That is not necessarily true for the synthetic materials and in fact an adduct or DNA damage has been characterized and identified this may be starting out from ground zero. We have no kind of damage like that is currently in the body, so there the issue of a threshold versus linear models becomes much more important in terms of a hazard identification. So that in fact an adduct has been characterized and I would probably say at this point the data is suggestive of that. That a DNA adduct is occurring that's related to the zeranol itself or zeralenone, but not convincing because that adduct has not been identified in terms of the altered nucleoside. In other words it could be just be altering the occurrence of naturallyoccurring adducts is a possibility. Although the date the Dr. Metzler has briefly presented is suggestive that such an adduct independent of the naturally-occurring adducts is in fact being formed.
Chairman
349. Thank you very much.
Mr. Christoforou (EC)
350. Mr. Chairman, I think we
have reviewed the potential to toxic and carcinogenic effects
of now all the substances in question. The next question is related
to the response the distinguished experts gave to the question
whether the JECFA report of 1987 and 1988 is taken into account
this type of evidence which you have been hearing this afternoon.
As you already noticed, this evidence has started appearing quite
late, I would rather put it roughly, mid 1980s and it is growing
very fast in this area. The scientists have replied that all
these aspects of genotoxicity, synergistic effect, long-term exposure
to these substances have indeed been taken into account in the
JECFA report. But there were very strong differences in my views.
For example Dr. Ritter would say that they have not addressed
mutagenicity for all hormones, they have not addressed definitive
studies for genotoxicity or carcinogenicity of combinations although
this is the preferred method for use. The other scientist, Dr.
Arnold for example, would say that genotoxicity and carcinogenicity
have been examined and Dr. André would say that synergistic
effects have not been taken into account. I would appreciate
if all the scientists could summarize once again whether this
synergistic effect, the long-term exposure and the potential effects
or increased effect from the use of combinations have indeed been
taken into account in the JECFA report. And if they have not
been taken into effect what is the consequences of that? Do we
have to review that report now in view of that evidence? Dr.
Ritter has said there is no compelling evidence that we need to
review it today. In his written reply he said the weight of evidence
would not appear to suggest that there is no, that they are genotoxic
and carcinogenic. So there are some variations and slight nuances
in the expression. So I would appreciate if we can come back
on this issue by hearing the five experts on this.
Chairman
351. Did you get the question
and could you, who would like to start? Dr. Ritter.
Dr. Ritter
352. Thank you Mr. Chairman.
In the written comments which I offered with regard to the xenobiotic
hormones, I think that it will be evident to all that MGA for
example, has not been subjected to a JECFA evaluation. As I indicated
earlier on in the day, my assessments were drawn primarily, let
me go further, they were drawn entirely from information which
was published in the open literature and obviously dominated by
JECFA reports and other ones. It is clear that MGA has not been
subjected to such an evaluation and consequently, I have no information
other than of a proprietary nature which I did not use, from these
evaluations to offer any public opinion on MGA. In so far as
the carcinogenicity testing of the combinations are concerned
it will also be evident to any reader of the JECFA reports, that
the assessments and conclusions offered therein are based on the
single compound that were evaluated by the Committee and it was
in that context that I offered those views. When I concluded
that there is no compelling evidence to suggest that these compounds
should be immediately re-evaluated, it was on the basis again
of my understanding not only of the historical reviews which have
been carried out by JECFA and other organizations, but indeed
how much more recent reviews, including those published as a result
of the European Conference on Growth Promotion in late 1995, early
1996, and indeed on the basis of the statements presented by our
colleagues here today, Dr. Liehr, Dr. Metzler and others. I think
as Dr. Liehr indicated, the work which he has carried out recently
the work which others made out recently, the work which others
have presented recently, suggest that there are circumstances
under which adverse effects may be demonstrated in association
with the multitude of these compounds. But I think the scientists
in my view have quite correctly noted that their relevance to
the doses at which this debate focuses is unknown, and I'm simply
suggesting that that is not in my view necessarily a reason to
argue that it should therefore be immediately redone. In other
words, let me put it another way, if Mr. Chairman, an organization
like JECFA or indeed a national regulatory authority, were to
immediately conclude that every evaluation that it had carried
out should always be subject to an immediate re-evaluation at
any time that a report indicating that there are circumstances
under which an adverse condition can be demonstrated with a particular
compound, then I would respectfully submit we will always be re-evaluating
everything that we had ever done. Because work goes on, not only
on these hormones but indeed on every substance that we can think
of. But as scientists, I think we are compelled to look at the
totality of the evidence as it's available. I think that totality
of evidence, certainly recognizing the information that has been
presented here today as well as the historical information, suggest
to me that the assessments that were provided then continue to
assure a reasonable degree of safety to consumers of these commodities.
As I say this is not only my opinion but in fact it was the conclusion
of a conference held very recently and sponsored by the European
Commission on exactly this issue. That these compound when used
in accordance with accepted practice, I should perhaps use a phrase
that we have all been using, good veterinary practice, good practice
in the use of veterinary drugs, whichever acronym you would like
to use. I think this has been the consensus view of this Conference
if you like. I use the word consensus because clearly in any
scientific endeavour of this sort one can quite properly and realistically
anticipate that there will be a divergence of opinion. The nature
of scientific interpretation is that legitimate bona fide
knowledgeable scientists may reach different conclusions from
the same set of data. But I think the consensus opinion of that
Conference Mr. Chairman, was that the weight of evidence
used then continues to prevail now, and that the assessments and
conclusions drawn then are still consistent with the available
information now. I think as Dr. Arnold has indicated, this in
no way is intended to cast any doubt or validity on the work which
others such as Dr. Liehr have performed. And certainly this sort
of work should continue, and I don't think anybody can assure
you that in some time down the road, that it will not require
or dictate that there be a re-evaluation. But as we sit here
in this room today, I continue to be of a view that those assessments
served the community well then, the international community, and
they continue to do so now. And that there has not been compelling
evidence that has been provided to suggest that those assessments
have been in serious error.
Chairman
353. Thank you very much. Professor
McLean.
Dr. McLean
354. Thank Mr. Chairman. I'll
be brief. I'd like to highlight the fact that in my submission
I made no comment about melengestrol acetate because there hasn't
been a large amount of data package available for evaluation and
so I restricted my comments to the other five hormones. The only
other comment I would make that if any national body or group
believe that the time for re-evaluation of some of the hormones
previously evaluated by JECFA was upon us, then I would invite
them to make an approach to JECFA as has been done on a number
of occasions with the number of compound of varying chemical classes.
It is interesting that if this information that has concerned
some has been so compelling, to ask why an approach to JECFA has
not been made.
Chairman
355. Thank you very much. Dr.
Arnold.
Dr. Arnold
356. Thank you Chairman. Concerning
the table I have presented in my written contribution, I just
wanted to facilitate the work of this Panel so that you don't
need to read all these documents and so I summarize the kind of
information, I was saying information pertaining to the effects
have been considered by the study, it's on page 9. I have not
stated that I felt that all this evidence was complete at that
time, I explicitly mentioned that some data had been completed
only at the 34th meeting of the Committee. This was only to facilitate
the discussion. What concerns the six substances, I made no statement
on melengestrol acetate because I haven't seen the data. The
only statement I made was on the availability of analytical methods
because this is something I know, but otherwise I have limited
my statements on the five endogenous hormones. I did however
say that from my point of view, the significant new evidence which
has been produced since that Committee did not invalidate the
basic conclusions and therefore I still am feeling very comfortable
with the conclusions although I admit that a lot of new evidence
has been produced by the scientific community. Coming to the
question of combinations the synergistic and antagonistic effects
of whatever, I had some difficulties to understand this question
because every time if we administer fixed combination to animals
or humans, it's quite clear and in all countries participating
in this dispute there are mechanisms that these fixed combinations
are evaluated. But I didn't understand the significance of these
questions when we are talking about the residue levels because
at those concentrations, all these substances occur simultaneously
in human beings of all sexes all ages and it's quite obvious that
these substances have both synergistic or antagonistic effects
in living animals including human beings. This is their normal
physiological function and they can synergize in one tissue in
one cell with respect to one effect and they can antagonize each
other. Therefore I had difficulties if these substances enter
the internal pools of the hormones they are immediately confronted
with all kinds of hormones, so I didn't understand what the question
meant at the residue level. At pharmacological levels of course
they are tested in all states if they are administered as fixed
combinations.
Chairman
357. Could you Professor Epstein
precise the question?
Dr. Epstein (EC)
358. I am sorry that my point
that I raised was so obscure. I would have thought that if you
add two carcinogens to an animal or to a human, you stand the
risk of interactions of one kind or another. There are data showing
that are positive interactive effects whether they be additive
or synergistic such as those between oestrogen and progesterone.
With oestrogen and progesterone together, produce a far greater
increase in mammary cancers in rodents than do either separately.
So that is clear what one means by synergism. I'm unaware of
any evidence of antagonistic, any experimental evidence of antagonistic
effects of any anabolics and would be happy if you could refer
me to the appropriate citations.
Dr. Arnold
359. I agree with Dr. Epstein
that there are examples of synergistic effects but I could list
a number of situations where these hormones counteract. I'm not
prepared at the moment to give you such references but I'm sure
I can do it tomorrow.
Chairman
360. Dr. Lucier.
Dr. Lucier
361. Probably the best example
is the one that you just cited; oestrogen and progesterone in
which oestrogen unopposed by progesterone causes an increase in
uterine cancer. If progesterone is given at the same time then
that effect is blocked. So where as oestrogen and progesterone
seem to synergize each other in terms of breast cancer risk, they
actually antagonize each other for uterine cancer risk. So it
just points to the fact that's very difficult to fully appreciate
the complexity of trying to estimate synergistic responses, additive
responses or antagonistic responses. Even the same two hormones
in different tissues will do exactly the opposite, one synergize,
the other antagonize.
Chairman
362. Thank you very much. Can
I give you the floor?
Dr. André
363. We will speak about the
six hormones and not of MGA, it is clear we are just speaking
about the other ones. I think that concerning this question when
JECFA has considered these hormones, they have been considered
as drugs, as classical drugs and for this reason, all the data
concerning toxicological assays has been asked to companies and
evaluated by very well scientific expert groups. But I think
they have not been evaluated as for the reviews for growth promoters,
I mean with a very large scale use. I think interference between
this large scale use of hormones and the other drugs used also
in animal breeding has never been studied, and its clear that
the use of hormones has been demonstrated to longer some withdrawal
period and elimination rates of other drugs. The probability
to have interference between two drugs when they are used for
therapeutic use is very small because you have no opportunity
to have at the same time two different illnesses and two drugs
at the same time. But when you are using such compounds in large
scale as hormones, then you have a higher probability to see on
the same animal at the same time the use of these hormones and
use of another drug. And I think in this particular case of growth
promoting substances, the assay has to be done. And concerning
the new scientific evidence we are speaking about very recent
data from this morning altogether and I would just make two remarks
that many of these data concerning mode of mechanism of action
carcinogenicity and other are recent data from '90 to now and
most of them have been published during 1995 and 1996, the two
last years. So this could also explain in some ways that many
of these data, recent data have not been taken into by the EC
Conference in '95 because the bibliography and the investigation
has been done for this Conference up to the beginning of '95 and
not more recently.
Chairman
364. Can I give you the floor?
Mr. Christoforou (EC)
365. Mr. Chairman, Dr. Liehr
would like to make a comment on the synergistic effects and then
Dr. Bridges would like to intervene on the so-called 1995 EC Scientific
Conference what was ....... during that Conference. Then if you
allow me I will summarize once again what was said I may be making
probably slightly legal but directly related question to what
is the JECFA standards in this case and what is the legal context
in which we are litigating in this case. I think that will be
important for our scientists. Thank you.
Dr. Liehr (EC)
366. Mr. Chairman, concerning
the synergism of hormones, I agree with Dr. Lucier who stated
that the combination of oestrogen plus progestin inhibits uterine
tumour formation whereas it appears to enhance mammary tumour
formation. It certainly does so in animals and the epidemiological
evidence in humans is also quite strong. In this context, I think
it is very important for all of us to realise that when several
hormones are combined and given as a combination that the balance
of hormones within the body, the regulation by various hormones
appears to be altered or influenced in ways that we have not sufficiently
taken into account. If for instance progestin inhibits uterine
tumour formation then and enhances mammary tumour formation, then
it is obvious that circulating within all of us are hormones in
a quite well-defined balance and as humans proceed through life,
through stages, the endocrine regulation is quite well balanced.
Once combinations of hormones are added this balance is being
destroyed and I think an obvious example of how this, effects,
synergistic effects can arise, is the fact that the metabolism
of oestrogen is clearly or has clearly been shown to be inhibited
by progestins. So combinations of hormones they easily alter
the balance between these, between endogenous hormone levels and
for the many synthetic progestins, I don't know to what extent
this is known. A number of synthetic progestins have been examined
but certainly not all of them. Thank you Mr. Chairman.
Chairman
367. Thank you very much.
Mr. Christoforou (EC)
368. Mr. Chairman before giving
the floor to Dr. Bridges, I would like to clarify one point and
Dr. Stephany will intervene just afterwards. Dr. Ritter has said,
JECFA evaluated only single compounds, single substances. From
what we know in the market, the implants, there is only one implant
that is one substance only marketed. All the others are implant
of compounds of similar substances and I think Dr. Stephany would
like to say a couple of words about this. So in fact, what it
is administered to the animals in this case, they are no single
substances except one. The majority of all the rest of the implants
are several compounds together. That I think Dr. Stephany would
like to say a couple of words on this.
Chairman
369. Yes? Dr. Ritter please.
Dr. Ritter
370. I don't want to pre-empt
the comments, but in addressing the issue of combinations, I'm
not sure if you are dealing with the issue of animal safety, who
presumably would be at greatest risk from the combination, if
the combination was to produce synergistic effects? Because I'm
left with the impression, perhaps these comments will be addressed,
that in terms of human safety, the issue is the exposure to the
levels which are present as food residues, which indeed are present
in combination with hundreds of other substances, not only these
two alone. So I'm not sure if the comments are intended to be
more relevant to the issue of safety in the cow, or to the issue
of safety to humans who consume commodities from which the residues
may indeed be present in combination but at very much reduced
levels and again in present in combination not only for the two
steroids in question, but indeed present in combination with hundreds
of other residues of both natural and exogenous origin.
Mr. Christoforou (EC)
371. Thank you, thank you very
much indeed. Because there is one aspect which is not practically
discussed in this room but has been argued in the submissions
of the parties, especially in submissions of the European Community.
This case concerns both the facts on human beings of course,
but also on animals, and we did not elaborate because the effects
on the animals are even more obvious than what the effects are
of this residue for human beings. But Dr. Stephany will also
given you some information on animal health also in this case,
that is the prostate of animals that are affected. Our question
is not only the potential effects of the animals but also the
potential effects of those combinations for human beings. And
the link that was made, has been explained, is since the implants
which are used on the market, apart from one the others are compounds
of several substances, this is linked to our question, what are
the possible synergistic effects of this combination? Has this
been studied by the JECFA Report? That was the aim or the point
that we were trying to make. But I give the floor first to Dr.
Stephany then will come back to Dr. Bridges. Thank you.
Dr. Stephany (EC)
372. Thank you Mr. Chairman.
First of all I have to make one very small correction, of the
implants that are on the market, there are two having a single
active component but only one having oestradiol and the other
one is zeranol. So there are two, one is oestradiol the brand
name is Compudose and the other one contains zeranol, xenobiotic
and the name is Ralgro. All others as far as I am aware are combinations
of having at least one xenobiotic hormonal active compound in
it. What surprises me a little is that we always talk about,
that the implants contain compounds that are identical to the
natural ones. That's simply not true because the implants contain
either the natural ones in chemical different form like an ester
like oestradiol benzoate and or the testosterone as a testosterone
propionate. And at least testosterone propionate what is xenobiotic
circulates freely in the body as is known from clinical chemical
studies, and I'm not aware of any residue studies of testosterone
propionate as such and it is certainly not true that all testosterone
propionate or all oestradiol benzoate only will hydrolyse and
will yield the natural identical hormones. So I think that's
one thing and coming or responding to the remarks of Dr. Ritter,
if you have two hormonal active components in your implants you
will have two at least two hormonal active residues. So the consumer
will in his food have, in between a wealth of other things, I
fully agree, the probability of being served with two hormonal
active hormones or residues at the same time, at least two different
ones. Well what's next? Oh the remark on animal health, it's
only a small remark. Some recent research in the Netherlands
with, picking up old research, we know that if you treat bull-calves
with oestrogenic compounds then at least a few organs will change
like the prostate and with some new technology based on histo-chemical
its a new thing, we found that at least this effect is much more
extended than we have found previously. Whether that will effect
the health of the animal as such, I can hardly say especially
for calves only having a full life of half a year. But at least
it's another signal that a lot of things change in the body of
the animal, besides that more meat is produced. And also that's
an item that is touched in the European Conference, ranging from
animal health to animal welfare, but that's completely another
thing. I think that's it for the moment, and once again I think
the most important thing is that the implants do not contain in
most cases natural identical compounds.
Chairman
373. Thank you could. I'm sorry
I missed before Dr. Randell he wanted to intervene. May I give
you the floor?
Dr. Randell (Codex)
374. Thank you Mr. Chairman.
I would not like the Panel to go away with the idea that JECFA
did not evaluate the residues present in animals from these mixed
implants. The monographs which were prepared by JECFA at the
32nd session clearly indicate that trials were done on mixed implants
as well as on single substances implants and exactly the sort
of mixtures that we have just heard, that is, oestradiol together
with testosterone; oestradiol together with progesterone; oestradiol
benzoate together with testosterone propionate and also oestradiol
with trenbolone acetate under the oestradiol evaluations. These
were known to JECFA at the time and the pharmacokinetics of these
substances as they were gradually metabolized and excreted by
the animals were studied by the experts at that time. Thank you.
Chairman
375. Sorry, Dr. Arnold.
Dr. Arnold
376. Thank you Mr. Chairman.
Dr. Stephany is absolutely right that the esters are administered.
However, this is also the case in the European Union. If these
substances are legally used for therapeutic purposes because,
and I think here the rules are entirely right, it is recognized
that the esters are readily hydrolyzed to yield the substances.
Therefore it doesn't make a great difference if we have talked
about oestradiol, testosterone and progesterone because these
esters are in fact readily hydrolyzed. The reason why the esters
are used is that the free substances are more slowly released
because we discussed this earlier today. The plasma half-life
is so short. However, in order to give you an idea how ineffective
these substances still are, when testosterone propionate was used
in earlier times as androgen substitution therapy, it was necessary
to inject 25 mg. every day intra-muscularly, so although he is
from an academic viewpoint entirely right, I think we can continue
discussing the effects of the free substances. Thank you.
Chairman
377. Thank you very much. I
give the floor back to the Community.
Dr. Bridges (EC)
378. Chairman, I'd just like
to clarify the nature of the December 1995 Conference because
several speakers have referred to it as if it was an up-to-date
comprehensive risk assessment on steroids. It wasn't really of
that nature at all, it had nearly 400 participants, which is a
pretty difficult way of going about risk assessment. It was covering
three areas, development of new growth promoters generally, risk
assessment across a range of growth promoters and then monitoring
and surveillance. So there wasn't and the way the papers were
identified was that we had a small organizing committee who chose
the speakers. Now in their wisdom or otherwise, they chose not
to have any body who was involved in genotoxicity and so as a
consequence, and I was a plenary speaker for risk assessment so
I remember the brief well, as a consequence this issue of genotoxicity
was not addressed at all by the conference and therefore the conclusions
of the Conference did not take it into account. So it isn't and
was never intended to be a comprehensive risk assessment and it
didn't really consider any other mechanism because of the way
the speakers were selected other than just to look at the hormonal
mechanism and how that may be related to cancer.
Chairman
379. Can I ask you, the fact
that you did not invite speakers, was that an indication that
this was not part of the mainstream thinking at the time, or?
Dr. Bridges (EC)
380. Chairman, I wasn't a member
of the organizing committee but they were clearly very wise because
they chose me as a plenary speaker so I couldn't argue with them.
I think really the thinking was that they wanted to follow up
to the so-called Lamming Report, and the Lamming Report had concentrated
very much on hormones acting as hormones or hormonal mechanism.
So I think the natural assumption was that they would get an
update on those sort of issues rather than look at broader issues
and I've taken the opportunity to talk to members of the organizing
committee recently to confirm that that was their view.
Chairman
381. But could it be said that
if this would be organized today they would probably take a different
approach? Is that, I mean these issues we're discussing have
they moved into the debate?
Dr. Bridges (EC)
382. I'm sure Chairman that if
we were organizing the same conference today, genotoxicity issues
would loom very large in the discussion and I'm sure I would have
had to refer to it particularly in my paper.
Chairman
383. Thank you very much. Dr.
Arnold.
Dr. Arnold
384. Thank you Mr. Chairman.
I totally agree with you that this Conference has not produced
the slightest element of risk assessment, I totally agree with
you. But I have recognized that some important information has
been disseminated including your own very important key lecture,
but I wanted to underline this Conference has not produced the
slightest element of risk assessment.
Chairman
385. Thank you very much. Dr.
Ritter please.
Dr. Ritter
386. Thank you Mr. Chairman.
I think it may be useful, a number of us have referred to the
report, I have the report with me which I brought at the risk
of great personal injury to transport it ... [tape ends]
Mr. Christoforou (EC)
387. It is addressed, particularly
for Dr. Ritter, Dr. McLean, Dr. Arnold and of course, Dr. Randell.
Chairman
388. Thank you very much. Could
I start with you Dr. Randell because the procedural questions
are addressed to JECFA.
Dr. Randell (Codex)
389. Thank you, Mr. Chairman.
390. First I'd like to say that
the JECFA Secretariat, of which I had the honour to be a part
for a period of my career, would feel very disturbed if they were
aware that data were available to the scientific community that
were not available to JECFA, or were not being proposed to be
available to JECFA, in a manner that would render JECFA's advice
to FAO and WHO member countries, either obsolete or inappropriate.
391. Therefore, my comment earlier,
was really to maintain, what I believe to be the standing excellence
of JECFA's evaluations in all of the fields that JECFA deals with,
in order that, we could perhaps encourage those scientists that
have these data to assemble them and bring them to JECFA for review.
It was meant as a positive, not a negative, statement.
392. A few minor corrections
to the history which we've just heard. The vote which took place,
in which the hormones were failed to be adopted by the Codex Commission,
was in 1991, not 1992.
393. The four principles concerning
the role of science in Codex decision-making, and the extent to
which other factors are taken into account, was never discussed,
as far as I am aware, by JECFA. It was not processed through
the JECFA system. It is entirely a Codex matter and, therefore,
entirely operated by the member governments of Codex and not by
the experts in JECFA.
394. Let me put the JECFA material
into perspective. JECFA provides advice to FAO and WHO and through
them to the members of those two organizations and also to the
Codex Alimentarius Commission.
395. The Codex Alimentarius Commission
has, as a matter of procedure, taken the JECFA recommendations
in a variety of areas and plugged them into the eight-step elaboration
system and the result of this, in most cases, is a consensus adoption
of these points of view which are then available for countries
to apply, if they feel that they wish to. They are not obliged
to under the Codex rules.
396. There have been any number
of emergency re-evaluations in JECFA which have been initiated
in Codex and which have found themselves reflected in Codex opinion.
397. As to the direct question
if there is one that has occurred in the nine-month period since
the entry into force of the Uruguay Round Agreements, I'd have
to check that in but I can't think of one. The most recent one
which has similar import would be the decision of JECFA to withdraw
previous evaluation in regard to potassium bromate, as a flour-treatment
agent, and the subsequent withdrawal by Codex of all approved
uses of potassium bromate in flour, primarily because potassium
bromate residues remain in the flour at the time of ingestion
by the human consumer, and potassium bromate is a carcinogen.
398. The maximum residue limits
are not exclusively concerned with trade. They are concerned
with the control of good agricultural or good veterinary practice
and they are applied in trade. To be quite practical about it,
it's definitely beneficial to trade if countries have the same
numerical values for maximum residue limits, or at least if you
are exporting a product, the level at which you are exporting
is lower than the limit applied by your importer.
399. However, the maximum residue
level should reflect the good agricultural, or good veterinary
practice, on your territory and not be linked exclusively to trade
considerations.
400. I would take umbrage at
the point that the MRL is a trade-derived figure. It is, in fact,
a figure derived from good veterinary or good agricultural practice.
Chairman
401. Can I ask you to go into
the question which was put forward?
Dr. Ritter
402. Very quickly, I think the
principle that was being elaborated, the philosophy is more popularly
referred to as the precautionary principle.
403. As to what is the most appropriate
action in the face of the kind of information, for example, that
has been presented today, I take that really to be the work of
the Panel, and so I will make no attempt to answer that question.
404. I think it goes well beyond
the jurisdiction that I've been provided here to comment.
405. I will, very quickly, comment
on, if you like, the age of the assessment and I've already made
comments on this a number of times, but it perhaps bears repeating.
406. I think it is incorrect
and I would respectfully submit that it is misleading to suggest
that 1988/1989 is the last time that this issue on the safety
of the hormones, in question, has been examined.
407. I've already mentioned that
certainly in my view, this issue, without going into a lengthy
debate as to whether or not the strict definition of risk assessment
was made by the European Conference, I think it goes without question
that the issue of the safety of the hormones, in the general sense,
was most certainly re-evaluated in December 1995, which is a little
more than one year ago.
408. Indeed, a number of people
who are here today were active participants at that conference.
409. I must say that I disagree
with the view that 1989 is the last time that this issue was formally
evaluated on an international level. I think that's incorrect
and I think it's misleading.
410. More specifically, on the
issue of risk assessment, whatever that means. We could spend
the rest of the evening debating whether or not risk assessment
have, or have not, formally been discussed by the Conference.
411. I would refer the Panel
to a specific section entitled, Risk Assessment, on page 3 of
the Conference Report, and it falls under the general section
of the Report entitled Report and Conclusions of the Steering
Committee, specific section entitled, Risk Assessment.
412. Although the Conference
was concerned with many technical matters, it is inevitable that
general interest should have centred on the risk assessment of
different classes of both promoting substances, the subject of
discussions of Working Group 2.
413. Then I would refer, Mr.
Chairman, the Panel to a number of specific papers which I would
respectfully submit, dealt with very much with the issue of risk
assessment. I refer to Workshop No. 2 on pages 245-401 and
I would refer specifically to a number of papers, including the
one presented by Professor Bridges, but also including papers
presented by Dr. Miller from the United States, Dr. Hoffmann
from Germany, and so on and so forth.
414. If I refer, just by way
of example, not to give particular preference to any one of these
papers, to the paper presented by Dr. Miller from the USFDA at
that Conference, she concluded, at that time, "hormonal growth
promoting agents include a variety of compound which very markedly
in pharmacology and biochemistry" so on and so forth.
415. "When these animal
drug products are used according to label directions, the edible
tissues from treated animals, are safe for all consumers."
416. I would respectfully submit,
Mr. Chairman, that that is very much an assessment of risk, regardless
of whether or not we can come to a formal definition of what constitutes
a risk assessment. It's certainly my view that this is most definitely
the element of risk assessment. It strikes the heart of what
a risk assessment is, because after all the product of a risk
assessment, is the statement of safety to the target population.
That's why we carry out risk assessments. It's not merely a
mathematical exercise.
417. I would suggest to the Panel
that there are a number of papers here that deal very much with
the issue of risk to human populations, resulting from the use
of these compounds, and that the consensus of this Workshop was
that the use of these compounds, as recently reviewed as December
of 1995, does not constitute any risk.
Dr. André
418. May I add some comments
for the Panel? It can also see in the same paper, page 378,
conference.
419. I will read what it says:
"New quantitative risk
assessment models are needed for the safety evaluation of chemicals
with toxic actions, like general carcinogen."
420. It's in the same paper so
it's not possible to extract something when you don't extract
all the information.
Dr. Ritter
421. I didn't intend to mislead.
I mean obviously I'm not going to read into the record the entire
Conference Report it is available.
422. There is no question that
a number of deficiencies, in terms of our state of knowledge,
as identified throughout the report, but those efficiencies, those
deficiencies were weighed in the conclusion which the Panel has
reached. They weren't weighed by me. But the conclusions of
the Working Group was that the present state of knowledge is sufficient
to demonstrate the safety, in their view, of the use of these
chemicals in contemporary times.
423. I think it would be silly
for any scientist to presume that the day will ever come, on this
issue or on any other, where we could say we know enough and that
there is no need to do any further work. I have never been associated
with a scientific issue where I have ever heard a scientist say,
there is no need to do any further work on this topic, we know
all that we need to know.
424. I agree that there is further
work that is indicated. I agree that statements made by scientists,
such as Dr. Liehr will continue to contribute to our understanding,
but I also agree that the totality of evidence re-evaluated, as
recently as December 1995, suggests that the way in which these
substances are used and the residues which they produce, do not
constitute a risk to human health.
425. I don't find those statements
to be contradictory at all.
Chairman
426. Dr. Lucier.
Dr. Lucier
427. My question may show a certain
amount of naivety but did JECFA document or the 1995 meeting address
the issue of carcinogen risk assessment, in any kind of way?
428. It seemed to me like the
risk was based on the hormonal activity of the agents, in primates.
Chairman 429. We discussed that briefly before. Would you like to give your views on this. TO CONTINUE WITH EC MEASURES ON MEAT - COMPLAINT BY THE U.S. |
|